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Abstract
Background: Acute Decompensated Cardiac Failure (ADCF) is frequently associated with deterioration in renal
function. Neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of kidney injury. We aimed to
determine if NGAL measured at admission predicts in-hospital acute kidney injury (AKI) in ADCF.
Methods: A prospective observational study measured NGAL and B-natriuretic peptide (BNP) from patients with
ADCF presenting to two tertiary hospitals. Patients received standard care and were followed up daily as inpatients.
ADCF was defined by PRIDE score ≥ 6 and AKI by RIFLE criteria.
Results: One hundred and two patients (median age 80, IQR 69-84 years, 52% male) were enrolled. AKI developed
in 22 (25%) of 90 for whom outcome data was available. Seven patients died. NGAL was significantly elevated in
those who developed AKI versus those who did not (median 130 ng/ml vs 69 ng/ml, p = 0.002). NGAL was also
higher in those who died (median 136 ng/ml vs 68 ng/ml, p = 0.005). AKI was significantly associated with risk of
death (5/22 (23%) vs 1/68 (1.5%), p = 0.001), but not length of hospital stay. NGAL significantly correlated with
admission eGFR but not BNP. For prediction of AKI, NGAL > 89 ng/ml had sensitivity of 68% and specificity of 70%
with area under the receiver operator characteristic (ROC) curve of 0.71 (0.58-0.84). After adjustment for baseline
renal function, the odds ratio (OR) for AKI was 3.73 (1.26-11.01) if admission NGAL > 89 ng/ml.
Conclusions: Elevated NGAL at admission is associated with in-hospital AKI and mortality in patients with ADCF.
However, it has only moderate diagnostic accuracy in this setting.
Background
Cardiac failure is frequently complicated by renal impair-
ment and this is associated with worse outcome [1-3].
Renal insufficiency, defined by estimated glomerular fil-
tration rate (eGFR) < 60 ml/min/1.73 m
2 had an overall
prevalence of 57% in an analysis of hospitalised patients
with heart failure, and was an independent predictor of
mortality [4]. In another study of patients admitted to
hospital with Acute Decompensated Cardiac Failure
(ADCF), 27% had subsequent deterioration of renal
function which was associated with increased mortality
and length of stay [5].
Neutrophil gelatinase-associated lipocalin (NGAL) has
been shown to be an early marker of acute kidney injury
(AKI) in a number of settings [6-9]. Mechanisms of kidney
injury in ADCF are multi-factorial, and in some instances
may be exacerbated by therapy such as diuretics [10-12].
Identification of patients at risk of subsequent deteriora-
tion in renal function may allow for individualised therapy
to mitigate this, for example by careful titration of loop
diuretic doses and avoidance of potential nephrotoxins
such as intravenous radiographic contrast media.
The purpose of this investigation was to determine
whether measurement of NGAL at presentation to the
Emergency Department (ED) could predict in hospital
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this marker in risk-stratification.
Methods
Design and setting
A prospective, observational, un-blinded study con-
ducted in the Emergency Department (ED) of two Uni-
versity hospitals in Western Australia between January
2010 and January 2011.
Population and patient selection
Patients presenting to the ED with symptoms consistent
with ADCF during rostered research nurse hours (7 days
per week 0700-2200) were screened for inclusion and
underwent testing for BNP to enable calculation of PRIDE
acute heart failure score [13]. A modified PRIDE score ≥ 6
(using a BNP cut-off of 400 pg/ml rather than NT-proBNP)
was considered diagnostic for ADCF. The hospital dis-
charge summary was reviewed to confirm diagnosis. Exclu-
sion criteria were age < 18 years and end-stage renal failure
on dialysis. Informed written consent was obtained from all
patients; in patients whose clinical condition at presentation
precluded informed discussion, we had provision for
‘deferred consent’ to enable processing of early blood sam-
ples. Ongoing participation in this circumstance required
the agreement of the next-of-kin, with consent obtained
from the patient as soon as their clinical condition allowed.
The study complied with the Declaration of Helsinki and
was approved by the Royal Perth Hospital Human Research
Ethics Committee (Reference EC 2009/097).
Biomarker analysis
Blood samples were taken when initial intravenous access
was obtained and prior to any intravenous therapy. BNP
and NGAL assays were undertaken immediately by
trained research personnel, with the Biosite Triage device
(Alere, Inverness Medical, Australia Inc) using whole
blood. We did not measure urine NGAL as this particu-
lar assay is designed only for blood. These results were
not made available to clinical staff. Additionally all
patients had electrolytes, urea, creatinine and troponin
tested on the Abbott Architect (troponin I) or Roche
Elecsys (troponin T) laboratory analyser. The NGAL
assay used had a lower limit of detection of 60 ng/ml,
and a manufacturer quoted 95
th percentile of 149 ng/ml,
which was used as a dichotomous cut off where appropri-
ate for the purposes of categorical analysis. Baseline esti-
mated glomerular filtration rate (eGFR) was calculated
using the admission creatinine level by the Modification
of Diet in Renal Disease (MDRD) formula [14].
Inpatient follow up
Patients were followed up daily by a research nurse.
Clinical data including vital signs, weight, fluid balance,
and significant investigations or interventions were
noted. Episodes of shock, sepsis, myocardial infarction
(determined from hospital discharge summary and
according to AHA/ESC criteria [15]), administration of
intravenous contrast, inotropic or ventilatory support
and renal dialysis were recorded. All medications admi-
nistered and dose changes were recorded. An increase
of 50% or more of baseline loop diuretic dose for at
least 24 hours, or the introduction of one of these
agents was considered clinically relevant. Potential
nephrotoxic agents such as ACE inhibitors were also
noted. Renal function was monitored by urine output
and daily serum creatinine. Patients were followed for
up to 7 days, or until death/hospital discharge, for deter-
mination of AKI. Mortality and duration of hospital stay
data was obtained from clinical records.
Outcome measures and sample size calculation
The primary study outcome was AKI developing during
the inpatient stay, defined by RIFLE criteria [16], using the
admission creatinine as baseline. RIFLE R (Risk) is defined
as fall in GFR ≥ 25% or creatinine rise ≥ 50% from base-
line, or a fall in urine output to < 0.5 ml/kg/hour for at
least 6 hours. Secondary outcome measures were duration
of hospital stay and in-hospital mortality. Sample size was
determined assuming AKI would develop in 20% of
patients and that elevation of NGAL > 149 ng/ml (95th
percentile) would confer a relative risk of 4 times for this
outcome. A total sample of 85 would be sufficient to
demonstrate this with power 0.8 and a 0.05. We aimed to
recruit 100 patients to allow for 15% margin for missing
data etc.
Statistical analysis
Continuous data is reported as mean ± SD or median +
IQR for parametric and non- parametric distributions
respectively and differences analysed by Student’s t-test or
Mann-Whitney U test as appropriate. Relationships
between continuous variables were assessed by Spearman’s
rank correlation coefficient. For proportions, univariate
analyses used Chi squared or Fisher’s exact test. Receiver
operator characteristic curves were plotted for NGAL,
eGFR and creatinine at admission. To adjust for admission
eGFR, we used logistic regression analysis. Goodness-of-fit
was assessed using the Hosmer and Lemeshow test. All
analyses were conducted using SPSS version 17 (SPSS Inc,
Chicago, IL, USA). 95% confidence intervals are quoted
and a p value < 0.05 considered significant.
Results
One hundred and two patients were recruited into the
study. Median age was 80 years (IQR 69-84 years) and
52 (51%) were male. Baseline characteristics of the study
population are shown in Table 1. Twelve patients did
Macdonald et al. BMC Cardiovascular Disorders 2012, 12:8
http://www.biomedcentral.com/1471-2261/12/8
Page 2 of 6not have subsequent data to enable determination of
AKI. These patients were either transferred to another
hospital after enrolment in the study, or were admitted
b u td i dn o th a v es u b s e q u e n tc r e a t i n i n em e a s u r e m e n t
prior to discharge or death. Of the remaining 90
patients, 22 (25%) had in-hospital AKI including one
patient who required short-term dialysis in the intensive
care unit in the context of cardiogenic shock complicat-
ing myocardial infarction. On examination of the hospi-
tal discharge diagnosis, ADCF was subsequently not
considered to be the primary diagnosis in 4 patients.
None of these developed AKI. The flow of participants
through the study is summarized in Figure 1.
Relationship between NGAL, eGFR and BNP
There was a significant relationship between NGAL and
admission eGFR (Spearman’s rho -0.42, p = 0.01) but not
between NGAL and BNP level (Spearman’s rho +0.13, p =
0.18).
NGAL and AKI
Figure 2 compares admission NGAL level between
those patients who developed in hospital AKI and those
who did not. Median NGAL level was 130 ng/ml (IQR
71-193 ng/ml) for those who developed AKI compared
to 69 ng/ml (IQR 60-103 ng/ml) for those who did not
(p = 0.002).
Mortality
Seven participants died during the hospital stay. Of
these, five had AKI and one did not (p = 0.002). One
further patient did not have subsequent renal function
data to enable classification. Median NGAL was 136
ng/ml (IQR 133-170 ng/ml) for patients who died ver-
sus 68 ng/ml (IQR 60-119 ng/ml) for those who did
not (p = 0.005).
Table 1 Participant characteristics and past medical history
n 102
Median Age (IQR) 80 (69-84)
Male 52 (51%)
Median BNP 723 pg/ml (IQR 337-1235 pg/ml)
Median PRIDE Score 12 (Range 6-14)
Congestive Cardiac Failure 50 (49%)
Hypertension 69 (68%)
Diabetes 46 (45%)
Coronary Heart Disease 60 (59%)
Valvular Heart Disease 19 (19%)
Chronic Obstructive Airways Disease 22 (22%)
Chronic Renal Impairment (admission eGFR < 60 ml/min/1.73 m
2) 62 (60%)
Figure 1 Study participant flowchart. RRT - Renal Replacement
Therapy, LOS - Length of Stay.
Figure 2 Neutrophil gelatinase associated lipocalin (NGAL) and
Acute Kidney Injury. Median NGAL 130 ng/ml (IQR 71-193 ng/ml)
in patients who subsequently developed AKI (n = 22) versus 69 ng/
ml (IQR 60-103 ng/ml) for those who did not (n = 68), p = 0.002
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Length of hospital stay was similar between those who
developed AKI and those who did not. Median admission
duration was 6.5 days (IQR 2-11 days) for the AKI group
and 6 days (IQR 2-10 days) for those without AKI (p =
0.96). This did not significantly change when patients
who died were excluded.
Predictive value of NGAL for AKI
Table 2 shows results of univariate analysis of variables
considered, a priori, likely to be associated with risk of
developing AKI. The manufacturer quoted cut off at the
95th percentile for NGAL is 149 ng/ml. In the present
study this value corresponded to a sensitivity of 45%
and specificity of 85% for AKI. A receiver operator char-
acteristic (ROC) curve (Figure 3) showed an optimal
NGAL cut off at > 89 ng/ml, with sensitivity of 68% and
specificity of 70% for AKI, with area under the curve
(AUC) of 0.71 (0.58-0.84). The AUC of the ROC curve
for admission eGFR was 0.72 (0.61-0.83) and for admis-
sion creatinine 0.70 (0.58-0.82). In addition to NGAL,
baseline renal impairment (as defined by admission
eGFR < 60 ml/min/1.73 m
2) was significantly associated
with AKI (Table 2). Four patients were subsequently
considered not to have ADCF. All of these had NGAL <
89 ng/ml and none developed ADCF. Excluding these
from the analysis did not significantly alter the results.
After adjustment for admission eGFR, odds ratio (OR)
for AKI was 3.73 (1.26-11.01) for NGAL > 89 ng/ml,
and 4.78 (1.49-15.30) for NGAL > 149 ng/ml. NGAL
was > 89 ng/ml in 14 of 19 patients (74%) with admis-
sion eGFR < 60 ml/min/1.73 m
2 who developed AKI,
and in one of 3 (33%) of those with admission eGFR ≥
60 ml/min/1.73 m
2 who developed AKI.
Discussion
The present study confirms that AKI is a common com-
plication of ADCF. Median NGAL is significantly higher
at admission in patients who developed AKI and in
those who died. Elevated NGAL at admission is asso-
ciated with AKI after adjustment for eGFR. AKI is asso-
ciated with increased risk of death but we did not find
any association with increased length of hospital stay as
has been found by other investigators [5]. This may
have been a chance finding as the study was not pow-
ered to assess these outcomes. Although NGAL identi-
fies a higher risk subgroup of patients for development
of AKI, in this study it was found to have only moderate
diagnostic accuracy.
Aghel et al [17] obtained NGAL levels on 91 admitted
patients with physician adjudicated ADCF. Thirty eight
percent of these developed worsening renal function
(WRF), defined by a rise in creatinine > 0.3 mg/dl, with
NGAL > 140 ng/ml having an odds ratio of 7.4 for
WRF, after adjustment for baseline eGFR. Higher NGAL
levels also increased risk of death. This study found
admission NGAL to have a sensitivity of 85% and speci-
ficity of 54%, compared to 68% and 70% in our study,
and found a higher NGAL cut off value. There were
important differences from our study which may explain
these discrepancies. We enrolled patients on arrival in
the ED using a pragmatic diagnostic tool rather than
selected by physicians after admission, when diagnostic
w o r k u pm a yb em o r ec o m p l e t e .T h ei n c i d e n c eo fr e n a l
Table 2 Univariate analysis of risk factors for AKI
FACTOR AKI No AKI Odds ratio
(95%CI)
P value
NGAL > 89 ng/ml 15/22 (68%) 20/68 (29%) 5.1 (1.8-14.5) 0.003*
NGAL > 149 ng/ml 10/22 (45%) 8/68 (12%) 6.1 (2.0-18.8) 0.002*
Age ≥ 80 years 10/22 (45%) 33/68 (49%) 1.3 (0.4-3.3) 0.81
eGFR < 60 ml/min/1.73 m
2 19/22 (86%) 35/68 (51%) 6.0 (1.6-22.0) 0.005*
Diabetes 10/22 (45%) 32/68 (47%) 0.9 (0.4-2.5) 0.90
Hypertension 16/22 (72%) 45/68 (66%) 1.4 (0.5-3.9) 0.57
Loop diuretic ↑
1 15/22 (68%) 43/68 (63%) 1.2 (0.4-3.5) 0.64
Nephrotoxic drug
2 7/22 (32%) 25/68 (37%) 0.8 (0.3-2.2) 0.64
IV Contrast 6/22 (27%) 15/68 (22%) 1.3 (0.4-4.0) 0.64
Sepsis 1/22 (4%) 1/68 (1.5%) 3.2 (0.2-54.0) 0.43
Shock 2/22 (9%) 4/68 (6%) 1.6 (0.3-9.4) 0.63
Myocardial Infarction 6/22 (27%) 9/68 (13%) 2.5 (0.8-8.0) 0.19
Urinary Infection 3/22 (14%) 5/68 (7%) 2.0 (0.4-9.1) 0.40
*p < 0.05
1 Introduction of loop diuretic or increase in usual dose of ≥ 50% over baseline for at least 24 hours (including bolus doses)
2 At least one dose of agent with potential renal toxicity including ACE inhibitor, angiotensin receptor blocker, non-steroidal anti-inflammatory drug,
spironolactone, aminoglycoside antibiotic etc.
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possible differences in illness severity, but there was a
high prevalence of renal impairment at admission, possi-
bly reflecting the higher median age in our study of 80
years. Finally the assays used were not the same. Differ-
ences in calibration of assays and antibodies used may
result in markedly different NGAL cut off values.
Unlike other conditions such as post surgery or intrave-
nous contrast administration where NGAL has be shown
to be useful for predicting AKI, the time of onset of the
renal insult is not easily determined in ADCF. Sixty per-
cent of patients in our study had admission eGFR < 60
ml/min/1.73 m
2. In the ED setting it is not clear whether
this represents chronic impairment or acute injury unless
information on stable baseline renal function is available.
In some patients, low GFR at admission may represent
AKI at its nadir, with subsequent recovery. Eight patients
with NGAL > 149 ng/ml did not develop AKI as defined
in this study. Some of these may have had renal injury
when compared to their stable baseline eGFR rather than
that recorded on admission. In addition, chronic renal
impairment itself is a major risk factor for AKI and it is
not surprising that low eGFR was significantly associated
with this outcome. This finding alone, in the absence of
elevated NGAL, should alert the clinician to a high risk of
subsequent worsening renal function.
The mechanisms of renal injury in cardiac failure, also
termed cardio-renal syndrome, are complex [10-12].
Renal hypoperfusion due to reduced cardiac output or
increased venous or abdominal pressures may contribute.
In addition high dose diuretics, intravenous contrast and
other drugs may result in renal injury. These factors may
explain why some patients who developed AKI in our
study did not have elevated NGAL on presentation.
NGAL has been shown to be elevated in patients with
stable chronic heart failure [18]. While known to be
released by renal tubular cells, expression of NGAL by
cardiac myocytes has also been demonstrated in heart
failure [19]. However a recent clinical study by Shrestha
et al [20] found no association between NGAL level and
echocardiographic parameters of systolic dysfunction.
Limitations
Limitations of this study include its un-blinded and obser-
vational nature. Data to assess subsequent renal function
was not available for all patients. This was most commonly
due to no subsequent bloods being taken due to early dis-
charge from hospital or transfer to another facility after
recruitment in the ED. In addition, we were restricted in
our ability to recruit overnight, a time when acute heart
failure presentations are common. The diagnosis of ADCF
was based on the clinical judgement of the treating clini-
cian and the PRIDE score rather than formal echocardio-
graphy. We used BNP rather than NT-BNP to calculate
this score. A BNP > 400 pg/ml cut point was chosen based
on manufacturer recommendation however its incorpora-
tion into the PRIDE score has not been validated. This
was a pragmatic study reflecting real life clinical practice
where initial treatment of ADCF is undertaken in the ED.
We did not have information on baseline renal function
and used worsening from admission to define AKI with a
single NGAL assay. However, ADCF is a dynamic condi-
tion and patients present to hospital at varying stages of
the illness; obtaining serial NGAL levels, and knowledge of
stable baseline renal function prior to acute decompensa-
tion would allow further exploration the timing of NGAL
peak in relation to nadir of renal function.
Potential clinical implications
Potential benefits of being able to identify patients at risk
of worsening renal function in ADCF are the ability to
modify treatment regimes to mitigate this risk. However,
as i n g l eN G A Ll e v e la ta d m i s s i o ni so n l ym o d e r a t e l y
accurate, although high levels are associated with higher
r i s ko fA K I .T h ei n c r e m e n t a lv a l u eo fN G A Li na d d i t i o n
to eGFR estimation in identifying high-risk patients is
uncertain. A statistical association with an outcome does
not necessarily translate into clinical utility for a biomar-
ker when added to existing clinical and laboratory risk
factors [21]. Further studies are required to determine
whether knowledge of NGAL level at admission trans-
lates into improved outcomes. NGAL may be a tool to
unravel the underlying pathophysiology of the cardio-
renal syndrome.
Figure 3 Receiver operator characteristic (ROC) curve for
prediction of AKI by NGAL measured at admission to hospital
(AUC - area under the curve).
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Elevated NGAL at admission is associated with in-hospi-
tal AKI, independent of baseline renal function, in
patients admitted from the ED with ADCF and is asso-
ciated with increased mortality. However, it has only
moderate diagnostic accuracy in this setting.
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